Abstract
Objective We utilized national claims-based data to identify the change in hazard of diagnosis of ALS following a possible ALS-related diagnosis (e.g., falls) and whether the change in hazard varies whether the patient lives in an urban or rural area.
Methods Health insurance claims data from both the commercial insurance market and Medicare supplemental market were obtained from the Merative MarketScan Commercial Claims and Encounters and Medicare Coordination of Benefits databases. Individuals with a diagnosis of ALS were identified and matched on age, sex, and enrollment period to individuals without ALS. For all individuals, inciting events such as falls, muscle related symptoms, or bulbar symptoms were also extracted. We then used fixed-effects regression to estimate the risk of being diagnosed with ALS following one of these events controlling for urban-rural status. Additionally, we utilized interaction terms to evaluate the effect of rurality on odds of diagnosis.
Results 19,126 individuals with ALS were included with 96,126 controls. Patients with ALS were more likely than matched controls to live in an urban area (87 vs 85%). Of those with ALS 84% had a symptom code preceding their diagnosis as compared to 51% in the general population. The association between having any symptoms and future diagnosis of ALS remained statistically significant after adjustment for confounders and an odds ratio of nearly 5. Odds ratios for the individual symptoms varied from 1.2 to over 10. In all models, living in an urban area was associated with increased odds of diagnosis with ALS while the effect of having a symptom was smaller among urban dwellers. Urban dwellers who are diagnosed with ALS are diagnosed at younger ages.
Conclusions Early diagnosis of ALS is vital for connecting patients with research and treatment options. These results suggest symptoms appear in the administrative health record potentially years before the diagnosis of ALS. Additionally, rural patients are diagnosed at later ages with a greater dependence on major symptoms than urban patients. These results highlight potential improvements for surveillance and screening for ALS.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Truven database was provided by the University of Iowa. Dr. Simmering was supported by a faculty fellowship through the Iowa Neuroscience Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of the University of Iowa waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
